ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination ...

Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic ...

At a median follow-up of 18 months, the OS rate was 95% and the DFS rate was 88%. 14 Long-term follow-up at a median of 53 ...

Andrea Necchi, MD, discusses how the findings from SunRISe-4 impact other data from the SunRISe group of clinical trials.

Panelists discuss how ruxolitinib has demonstrated efficacy as a second-line treatment strategy for chronic graft-versus-host ...

The phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard ...

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease ...

Sarah Sammons, MD, medical oncologist, clinical investigator in the Breast Oncology Center, associate director of the ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and ...

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in ...

The ARANOTE trial confirmed radiographical PFS benefit to adding darolutamide to androgen deprivation therapy without ...